Delayed
Hong Kong S.E.
11:37:30 2024-05-16 pm EDT
|
5-day change
|
1st Jan Change
|
27.65
HKD
|
+0.55%
|
|
-0.18%
|
-3.32%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
4,606
|
5,714
|
3,111
|
4,266
|
4,445
|
4,456
|
-
|
-
|
Enterprise Value (EV)
1 |
4,606
|
5,714
|
3,111
|
4,266
|
4,445
|
4,456
|
4,456
|
4,456
|
P/E ratio
|
35.1
x
|
47.2
x
|
21.8
x
|
32.6
x
|
28.3
x
|
21.9
x
|
16.7
x
|
13.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.1
x
|
15.9
x
|
-
|
7.28
x
|
5.9
x
|
4.55
x
|
3.48
x
|
2.68
x
|
EV / Revenue
|
16.1
x
|
15.9
x
|
-
|
7.28
x
|
5.9
x
|
4.55
x
|
3.48
x
|
2.68
x
|
EV / EBITDA
|
-
|
42,534,660
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-68
x
|
-
|
96.9
x
|
27.8
x
|
20.2
x
|
FCF Yield
|
-
|
-
|
-
|
-1.47%
|
-
|
1.03%
|
3.59%
|
4.96%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
166,000
|
166,000
|
166,000
|
168,000
|
170,998
|
175,107
|
-
|
-
|
Reference price
2 |
27.75
|
34.42
|
18.74
|
25.39
|
25.99
|
25.44
|
25.44
|
25.44
|
Announcement Date
|
3/19/20
|
3/19/21
|
3/18/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
286.5
|
358.4
|
-
|
585.9
|
752.8
|
979
|
1,282
|
1,664
|
EBITDA
|
-
|
134.3
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
112.4
|
-
|
145.3
|
178.3
|
208
|
272
|
347
|
Operating Margin
|
-
|
31.35%
|
-
|
24.8%
|
23.69%
|
21.25%
|
21.22%
|
20.85%
|
Earnings before Tax (EBT)
1 |
-
|
137.1
|
-
|
144.5
|
175.1
|
206
|
270
|
345
|
Net income
1 |
-
|
121.4
|
143
|
131.7
|
153.2
|
199
|
260
|
331
|
Net margin
|
-
|
33.86%
|
-
|
22.48%
|
20.35%
|
20.33%
|
20.28%
|
19.89%
|
EPS
2 |
0.7900
|
0.7300
|
0.8600
|
0.7800
|
0.9200
|
1.160
|
1.520
|
1.940
|
Free Cash Flow
1 |
-
|
-
|
-
|
-62.75
|
-
|
46
|
160
|
221
|
FCF margin
|
-
|
-
|
-
|
-10.71%
|
-
|
4.7%
|
12.48%
|
13.28%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
23.12%
|
61.54%
|
66.77%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/19/20
|
3/19/21
|
3/18/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-62.7
|
-
|
46
|
160
|
221
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
11.4%
|
13.7%
|
15.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
243
|
-
|
150
|
100
|
100
|
Capex / Sales
|
-
|
-
|
-
|
41.51%
|
-
|
15.32%
|
7.8%
|
6.01%
|
Announcement Date
|
3/19/20
|
3/19/21
|
3/18/22
|
3/20/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
25.44
CNY Average target price
32.25
CNY Spread / Average Target +26.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -3.32% | 621M | | +11.57% | 126B | | -4.96% | 11.27B | | +3.22% | 9.12B | | +38.90% | 5.61B | | -21.83% | 4.75B | | +8.74% | 3.45B | | -6.82% | 2.89B | | -13.32% | 2.07B | | -6.99% | 2.05B |
Medical Devices & Implants
|